QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
NASDAQ:BLU

BELLUS Health (BLU) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$14.74
$14.75
50-Day Range
$14.42
$14.75
52-Week Range
$6.38
$14.76
Volume
3.45 million shs
Average Volume
3.08 million shs
Market Capitalization
$1.87 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.75

BELLUS Health MarketRank™ Stock Analysis

Analyst Rating
Hold
2.25 Rating Score
Upside/​Downside
0.1% Upside
$14.75 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.97) to ($1.00) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.10 out of 5 stars

Medical Sector

927th out of 938 stocks

Biotechnology Industry

27th out of 28 stocks

BLU stock logo

About BELLUS Health Stock (NASDAQ:BLU)

BELLUS Health Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. BELLUS Health Inc. was incorporated in 1993 and is based in Laval, Canada. As of June 28, 2023, BELLUS Health Inc. operates as a subsidiary of GSK plc.

BLU Stock News Headlines

Did You Get Your Free Bitcoin Yet?
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
CBD Dosage: How Much Should You Take?
Bellus Health (NASDAQ: BLU)
A lot of people are making this costly mistake
You may have heard the saying “options are risky” … And, they can be. But only if you use them the way a lot of folks do. A lot of people think of BUYING speculative options when they talk about options. And BUYING low probability, speculative options is definitely risky… It’s how some folks leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time.
BLU.TO - BELLUS Health Inc.
BTIG Reaffirms Their Hold Rating on BELLUS Health (BLU)
Closing Bell: Bellus Health Inc up on Tuesday (BLU)
BELLUS Health Announces Meeting Updates
LifeSci Capital Reaffirms Their Hold Rating on BELLUS Health (BLU)
Why BELLUS Health Stock Is Rocketing Higher Today
See More Headlines
Receive BLU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BELLUS Health and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
3/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:BLU
Employees
74
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$14.75
High Stock Price Target
$14.75
Low Stock Price Target
$14.75
Potential Upside/Downside
+0.1%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
4 Analysts

Profitability

Net Income
$-76,080,000.00
Net Margins
-578,586.63%
Pretax Margin
-578,226.56%

Debt

Sales & Book Value

Annual Sales
$15,000.00
Price / Sales
124,613.93
Book Value
$3.09 per share

Miscellaneous

Free Float
96,162,000
Market Cap
$1.87 billion
Optionable
Not Optionable
Beta
0.19
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Mr. Roberto Francesco BelliniMr. Roberto Francesco Bellini (Age 43)
    Pres, CEO & Director
    Comp: $790.35k
  • Mr. Ramzi Benamar (Age 50)
    Chief Financial Officer
    Comp: $650.48k
  • Dr. Andreas Orfanos FFPM (Age 64)
    M.B.B.Ch, MBA, Chief Operating Officer
    Comp: $417.58k
  • Dr. Denis Garceau Ph.D. (Age 66)
    Chief Scientific Officer
    Comp: $496.56k
  • Dr. Catherine M. Bonuccelli M.D. (Age 65)
    Chief Medical Officer
    Comp: $741.66k
  • Mr. Daniel Matthews
    Director of Investor Relations & Communications
  • Mr. Tony Matzouranis (Age 50)
    Chief Bus. Officer
  • Mr. Sebastien Roy (Age 47)
    Corp. Sec.

BLU Stock Analysis - Frequently Asked Questions

Should I buy or sell BELLUS Health stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BELLUS Health in the last year. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" BLU shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BLU, but not buy additional shares or sell existing shares.
View BLU analyst ratings
or view top-rated stocks.

What is BELLUS Health's stock price target for 2024?

4 analysts have issued twelve-month price objectives for BELLUS Health's stock. Their BLU share price targets range from $14.75 to $14.75. On average, they predict the company's stock price to reach $14.75 in the next year. This suggests a possible upside of 0.1% from the stock's current price.
View analysts price targets for BLU
or view top-rated stocks among Wall Street analysts.

How were BELLUS Health's earnings last quarter?

BELLUS Health Inc. (NASDAQ:BLU) issued its earnings results on Wednesday, November, 10th. The company reported ($0.29) earnings per share for the quarter, missing analysts' consensus estimates of ($0.22) by $0.07. BELLUS Health had a negative trailing twelve-month return on equity of 24.27% and a negative net margin of 578,586.63%.

What other stocks do shareholders of BELLUS Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BELLUS Health investors own include Big Lots (BIG), Party City Holdco (PRTY), Washington Prime Group (WPG), Akorn (AKRXQ), Akers Biosciences (AKER), Akebia Therapeutics (AKBA), Adamis Pharmaceuticals (ADMP), ADMA Biologics (ADMA) and Acasti Pharma (ACST).

This page (NASDAQ:BLU) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners